The Center for Rheumatic Disease, Allergy, and Immunology
Kansas City, Missouri, 64111, United States
NCT Number: NCT00519363
This is an open label pilot clinical trial on a cohort of 15 Lupus patients from the Center for Rheumatic Disease. Clinical evaluations and laboratory tests will be done and then if eligible, the patients will receive oral atorvastatin, at a fixed dose of 40mg/day. Statins have been shown to induce clinical improvement in rheumatoid arthritis patients, as well as lupus patients. The effectiveness has been noted within 8 to 14 days, we will do our study for 3 months. Clinical and laboratory tests will be checked at the 1 and 3 month interval. We hypothesize that statin drugs (atorvastatin) slow the progression of SLE(Systemic Lupus Erythematosus) disease activity and down regulates TLR(Toll-like receptors) 2,4,and 9 pathways in addition to lowering lipid levels.
Looking for future studies?
Notify Me18 year–60 year
Female
Interventional
Phase 1 / Phase 2
Kansas City, Missouri, 64111, United States
Atorvastin (Lipitor) is a commonly used drug approved by the FDA for treatment of dyslipidemias. It is a relatively safe drug to use with periodic monitoring.
Eligibility critera:
Exclusion criteria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
atorvastatin 40mg, given orally daily for 3 months.
Other names: Lipitor 40mg
Time frame: 3 months
Time frame: 3 months
Looking for future studies?
Notify MeThe Center for Rheumatic Disease, Allergy, & Immunology
Other
Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07840573
Autoimmune Diseases, Connective Tissue Diseases
Houston, Texas, United States
View Trial DetailsNCT04902807
APECED, Arthritis
Paris, France
View Trial DetailsNCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial DetailsNCT05818254
Autoimmune Diseases, Connective Tissue Diseases
Chicago, Illinois, United States
View Trial Details